These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11602342)

  • 1. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.
    Cadwell C; Zambetti GP
    Gene; 2001 Oct; 277(1-2):15-30. PubMed ID: 11602342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promyelocytic leukemia protein is required for gain of function by mutant p53.
    Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
    Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor p53 and its gain-of-function mutants in cancer.
    Liu J; Zhang C; Feng Z
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells].
    Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP
    Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the biological activities of wild-type and mutant p53.
    Zambetti GP; Levine AJ
    FASEB J; 1993 Jul; 7(10):855-65. PubMed ID: 8344485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain of function mutations in p53.
    Dittmer D; Pati S; Zambetti G; Chu S; Teresky AK; Moore M; Finlay C; Levine AJ
    Nat Genet; 1993 May; 4(1):42-6. PubMed ID: 8099841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of p53 in the normal control of cell proliferation.
    Milner J
    Curr Opin Cell Biol; 1991 Apr; 3(2):282-6. PubMed ID: 1953903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control.
    Garkavtsev I; Grigorian IA; Ossovskaya VS; Chernov MV; Chumakov PM; Gudkov AV
    Nature; 1998 Jan; 391(6664):295-8. PubMed ID: 9440695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functions of the p53 protein in growth regulation and tumor suppression.
    Lin J; Wu X; Chen J; Chang A; Levine AJ
    Cold Spring Harb Symp Quant Biol; 1994; 59():215-23. PubMed ID: 7587073
    [No Abstract]   [Full Text] [Related]  

  • 12. Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo.
    Palacios G; Moll UM
    Oncogene; 2006 Oct; 25(45):6133-9. PubMed ID: 16682948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5.
    Kobayashi T; Ishida J; Musashi M; Ota S; Yoshida T; Shimizu Y; Chuma M; Kawakami H; Asaka M; Tanaka J; Imamura M; Kobayashi M; Itoh H; Edamatsu H; Sutherland LC; Brachmann RK
    Int J Cancer; 2011 Jan; 128(2):304-18. PubMed ID: 20309933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
    Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
    Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
    Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
    Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.
    Scian MJ; Stagliano KE; Deb D; Ellis MA; Carchman EH; Das A; Valerie K; Deb SP; Deb S
    Oncogene; 2004 May; 23(25):4430-43. PubMed ID: 15077194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway.
    Yu DH; Fan W; Liu G; Nguy V; Chatterton JE; Long S; Ke N; Meyhack B; Bruengger A; Brachat A; Wong-Staal F; Li QX
    Exp Cell Res; 2006 Apr; 312(6):865-76. PubMed ID: 16413018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effect of mutant and wild-type p53 on global gene expression.
    O'Farrell TJ; Ghosh P; Dobashi N; Sasaki CY; Longo DL
    Cancer Res; 2004 Nov; 64(22):8199-207. PubMed ID: 15548685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.